Advertisement

Digestive Diseases and Sciences

, Volume 55, Issue 11, pp 3120–3123 | Cite as

Efficacy of Standard Triple Therapy in the Treatment of Helicobacter pylori Infection: Experience from Kuwait

  • Waleed M. Alazmi
  • Waleed Buhaimed
  • Khalid Al-Mekhaizeem
  • Iqbal Siddique
Original Article

Abstract

Introduction

Recent studies suggest that the initial treatment success rates for H. pylori infection are falling below 80% in many parts of the world.

Aim

The aim of this study was to evaluate the efficacy of standard triple therapy in the treatment of H. pylori infection in Kuwait.

Methods

Consecutive H. pylori positive patients were enrolled in the study to receive clarithromycin, amoxicillin and omeprazole for 10 days. H. pylori status was checked with 13C urea breath test 6 weeks after the end of therapy. Endoscopic findings was recorded in all patients.

Results

One hundred forty-one patients (82 male and 59 females; mean age 41.8 years) were enrolled in the study. A total of seven patients were excluded from the per protocol analysis. The eradication rates in intention to treat (ITT) and per protocol (PP) were 72.3% (95% CI 64.2–79.5%) and 76.1% (95% CI 68–83%), respectively. The main endoscopic findings were normal in 47.5% and gastritis in 37.6%.

Conclusion

The efficacy of the current standard triple therapy for H. pylori eradication in our community is suboptimal. Confirmation for H. pylori eradication with noninvasive tests is recommended, especially in high-risk patients. New antimicrobial regimens for H. pylori eradication are considered necessary.

Keywords

Helicobacter pylori Triple therapy Kuwait Gastritis 

References

  1. 1.
    Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136:1863–1873.CrossRefPubMedGoogle Scholar
  2. 2.
    Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht III consensus report. Gut. 2007;56:772–781.CrossRefPubMedGoogle Scholar
  3. 3.
    Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985–1001.CrossRefPubMedGoogle Scholar
  4. 4.
    Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374.CrossRefPubMedGoogle Scholar
  5. 5.
    Albert JM, Al-Mekhaizeem K, Neil L, et al. High prevalence and level of resistance of metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. Aliment Pharmacol Ther. 2006;24:1359–1366.CrossRefGoogle Scholar
  6. 6.
    De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15-year period. J Antimicrob Chemother. 2007;59:783–785.CrossRefPubMedGoogle Scholar
  7. 7.
    Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136:13–24.PubMedGoogle Scholar
  8. 8.
    Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20:820–823.CrossRefPubMedGoogle Scholar
  9. 9.
    Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002;7:306–309.CrossRefPubMedGoogle Scholar
  10. 10.
    Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–1600.CrossRefPubMedGoogle Scholar
  11. 11.
    Lam SK, Talley NJ. Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998;13:1–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Gisbert JP, Pajares JM. Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis. 2001;19:134–143.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Waleed M. Alazmi
    • 1
    • 2
  • Waleed Buhaimed
    • 1
  • Khalid Al-Mekhaizeem
    • 1
  • Iqbal Siddique
    • 1
  1. 1.Thunayan Alghanim Center of GastroenterologyAmiri HospitalKuwait CityKuwait
  2. 2.Kuwait UniversitySafat, Kuwait CityKuwait

Personalised recommendations